1 / 24

Additional Benefit of Montelukast in Patients with Both Asthma and Allergic Rhinitis

Additional Benefit of Montelukast in Patients with Both Asthma and Allergic Rhinitis. Analysis from the COMPACT Trial Price DB 1 , Swern AS 2 , Tozzi CA 2 , Philip G 2 , Polos P 2 , Yu Q 2 Originally presented at the World Allergy Organization Congress (XVIII ICACI),

Anita
Télécharger la présentation

Additional Benefit of Montelukast in Patients with Both Asthma and Allergic Rhinitis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Additional Benefit of Montelukast in Patients with Both Asthma and Allergic Rhinitis Analysis from the COMPACT Trial Price DB1, Swern AS2, Tozzi CA2, Philip G2, Polos P2, Yu Q2 Originally presented at the World Allergy Organization Congress (XVIII ICACI), Vancouver, BC, Canada - September 10, 2003 Abstract published in Allergy & Clinical Immunology International 2003, Suppl. 1:29 abstract O-15-1 1 General Practice and Primary Care, University of Aberdeen, Aberdeen, UK 2 Merck & Co., Inc., Rahway, New Jersey, USA

  2. Clinical Observation of Montelukast as a Partner Agent for Complementary Therapy Price DB, Hernandez D, Magyar P et al. Thorax 2003;58:211-216

  3. Background • Asthma and allergic rhinitis frequently coexist1 • Rhinitis occurs in 75% of patients with allergic asthma and 80% of patients with non-allergic asthma • The same triggers (e.g., allergens) can cause rhinitis and asthma • Actively treated rhinitis is a risk factor for asthma exacerbations1 • Upper and lower airways share a common & probably interconnected inflammatory process • Common inflammatory cells: mast cells, eosinophils, T-cells2 • Common inflammatory mediators: histamine, leukotrienes, cytokines3 • Bronchial challenge leads to nasal inflammation, and nasal challenge leads to bronchial inflammation3 1. Price D, Thomas M. ERS 2002 2. Bousquet J and the ARIA Workshop Group J Allergy Clin Immunol 2001;108(5):S147-S334 3. Management of Allergic Rhinitis and its Impact on Asthma (ARIA) Pocket Guide.A Pocket Guide for Physicians and Nurses. 2001

  4. Background • Optimal management of rhinitis may improve coexisting asthma1 • Montelukast is approved to treat asthma and recently has gained approval for allergic rhinitis in several countries • Argentina, Czech Republic, Mexico, New Zealand, United States, etc. 1. Bousquet J and the ARIA Workshop Group J Allergy Clin Immunol 2001;108(5):S147-S334

  5. COMPACT Study Objectives To determine the effect of: • Adding montelukast to inhaled budesonide 800 mg daily versus • Doubling the dose of inhaled budesonide from 800 mg daily to 1600 mg daily

  6. Inclusion Criteria for COMPACTStudy • Adults (15 to 70 years) with chronic asthma for >1 year • Using inhaled corticosteroids for >12 weeks • Dose range: 600 to 1200 µg/day (of BDP or equivalent) • Asthma not optimally controlled (judged by investigator) • Baseline FEV1 or PEF value >50% predicted • -agonist reversibility • >12% in FEV1 or >15% in PEF at randomisation visit, or • Predefined PEF variability >20% • Minimal level of daytime symptoms and b-agonist use during the 2 weeks pre-randomisation

  7. Period II Active treatment (12 weeks) Double-blind Period IRun-in (4 weeks) Single-blind n=448 Montelukast 10 mg once daily + Budesonide 400 µg twice daily Budesonide 400 µg twice daily Budesonide 800 µg twice daily n=441 0 1 4 16 8 12 Weeks Study Design

  8. Objective of this Analysis • To determine if treatment with montelukast added to budesonide (400 g twice daily), compared with budesonide (800 g twice daily), provides additional benefit to patients with co-existing asthma and allergic rhinitis

  9. Statistical Analysis • All patients with a baseline and at least one on-treatment value were included in this intention-to-treat analysis • Treatment comparisons were based on an analysis of covariance (ANCOVA) model, with corresponding baseline value included as a covariate and treatment group as a factor • All analyses of patient subgroups were post hoc

  10. Definition of Groups in Analysis • Asthma+AR Patients with asthma and allergic rhinitis, defined by both positive patient history and confirmed physician diagnosis • Asthma–AR Patients with asthma but without both a patient history and physician diagnosis of allergic rhinitis

  11. Patient Demographic Characteristics Asthma+AR Asthma–ARN=410 N=479 Age, years median (range) 43 (15-74) 45 (15-75) Race, n (%) Caucasian 319 (77.8) 365 (76.2) Black 4 (1.0) 2 (0.4) Hispanic 46 (11.2) 82 (17.1) Other41 (10.0) 30 (6.3) Gender, n (%) Male 171 (41.7) 184 (38.4) Female239 (58.3) 295 (61.6)

  12. Patient History

  13. Patient Baseline Characteristics Asthma+ARAsthma–AR N=410 N=479 AM PEF median (range) 381 (89-870) 360 (62-875) Eosinophils median (range)0.24 (0-1.59) 0.23 (0-2.12) Using Rhinitis Meds Prestudyn (%) n (%) Intranasal steroid (INS)14 (3.4) 9 (1.9)Antihistamines (A)41 (10.0) 15 (3.1) Other treatments (O)12 (2.9) 10 (2.1) INS or A or O 57 (13.9) 30 (6.3)

  14. Change in AM PEF Total Group p=0.36 Weeks * Montelukast 10 mg once-daily along with budesonide 400 g twice-daily. ** Budesonide 800 g twice-daily

  15. Change in AM PEFTotal Group * Montelukast 10 mg once-daily along with budesonide 400 g twice-daily. ** Budesonide 800 g twice-daily

  16. p<0.03 Change in AM PEFAsthma+AR Patient GroupPost Hoc Analysis Weeks * Montelukast 10 mg once-daily with budesonide 400 g twice-daily. ** Budesonide 800 g twice-daily

  17. Change in AM PEFAsthma+AR Patient Group * Montelukast 10 mg once-daily along with budesonide 400 g twice-daily. ** Budesonide 800 g twice-daily

  18. Change in AM PEFAsthma+AR Patients: Using Rhinitis Meds§Post Hoc Analysis p<0.02 Weeks § Intranasal steroids or antihistamines or other treatments for rhinitis * Montelukast 10 mg once-daily along with budesonide 400 g twice-daily. ** Budesonide 800 g twice-daily

  19. Change in AM PEFAsthma+AR Patients: Using Rhinitis Meds§ § Intranasal steroids or antihistamines or other treatments for rhinitis * Montelukast 10 mg once-daily along with budesonide 400 g twice-daily. ** Budesonide 800 g twice-daily

  20. Percent Increase in AM PEFin Different AR Subgroups Percentages calculated using LS mean for change and baseline mean § Intranasal steroids or antihistamines or other treatments for rhinitis * Montelukast 10 mg once-daily along with budesonide 400 g twice-daily. ** Budesonide 800 g twice-daily

  21. Results • Adding montelukast significantly improved AM PEF in patients who had both asthma and allergic rhinitis (defined by both patient history and physician diagnosis), versus doubling the dose of inhaled budesonide • Treatment effect was greatest in patients taking medications for rhinitis at randomization • Doubling the dose of budesonide was less effective for asthma than adding montelukast in patients with both allergic rhinitis and asthma • Patients with both allergic rhinitis and asthma – who were also taking medications for rhinitis – showed minimal improvement in AM PEF with doubling the budesonide dose

  22. Conclusion • In the subgroup ofpatients from the COMPACT study who had both asthma and allergic rhinitis, adding montelukast to budesonide provided greater benefit in reducing airflow obstruction, compared with doubling the dose of budesonide

  23. Acknowledgment The authors express gratitude to the study centers and investigators: • Argentina: Baena-Cagnani CE, Lopez AM, Nannini LJ, Neffen H, Callejas O, Rey CA, Rojas R, Taborda J • Australia: Bryant D, Dennis C, Holmes P • Austria: Eckmayr J, Kummer F, Obermair H, Roger MG, Vetter N, Wanka W, Wild M, Wildner C, Zwick H • Belgium: Dierickx H, Mestdagh J, Rombouts L, Schatteman E, Schoofs H • Brazil: Fiterman J, Barreto SM • Canada: Laviolette M • China: Lin J, Luo W, Zhong NS, Zhou X • Colombia: Naranjo F • Finland: Rossi O, Toljamo T, Torkko M • Germany: Becker J, Beeh KM, Harnest U, Linnhoff A, Mikloweit P, Mitlehner W, Schmidtmann S, Schultebraucks R, Seevers C, Stutz P • Greece: Christaki P, Gaga A, Galanis N, Gourgoulianis G, Cratsiou C, Konstantopoulos S, Papadakis NE, Papageoriou G, Siafakas N • Hungary: Baliko Z, Berta G, Csontos Z, Herjavecz I, Kraszko P, Nekam K, Namenyi M, Magyar P, Szuks Z • Italy: Centanni S, Di Maria GU, Fabbri LM, Schmid G • Mexico: Acuna M, Hernandez D, Perez R, Salazar R • Netherlands: Aalbers R, Bantje T, Bax AJM, Creemers JPHM, Harreveld A, Van Kralingen K, Kuipers A, Luursema P, Van Noord J, Rijssenbeek-Nouwens LHM, Sinninghe Damst HEJ, Van Weelden BM, Wever AMJ • Norway: Bergmann A, Johansen B, Langaker KE • Portugal: Almeida J, Arrobas AM, Miranda MS, Segorbe AL • Romania: Radu JR, Stoicescu IP • Spain: Ercoreca IA, Hernandez JC, Olaguibel-Rivera JM, Pelaez A, Prieto-Andres JL, Reques FG, Rodriguez JR, Sanz CC • Sweden: Johansson G, Lind A, Lundback B, Spjuth A • Switzerland: Graf HJ, Gumowski P, Pons M, Spertini F • Taiwan: Chiang CD, Wang JH • UK: Barnes N, Corris P, O’Connor B, Dilworth P, Fahmy M, Fletcher P, James IB, Price DB • Venezuela: Montes De Oca MDC

  24. This information is provided as a professional service by Merck & Co., Inc. The views expressed in this presentation reflect the experience and opinions of the authors and not necessarily that of Merck & Co., Inc. or any of its affiliates. For detailed prescribing information on any product discussed in this presentation, please consult the physician circular or instruction booklet issued by the manufacturer before initiating therapy or procedures. Used with author permission.

More Related